Day: August 29, 2025
TORONTO and KNOXVILLE, Tenn., Aug. 28, 2025 (GLOBE NEWSWIRE) — Solar Alliance Energy Inc. (‘Solar Alliance’ or the ‘Company’) (TSX-V: SOLR, OTC: SAENF), a leading solar energy solutions provider focused on the commercial and utility solar sectors, announces that trading of its common shares will be reinstated on the TSX Venture Exchange (“TSXV“) at the opening of the market on or about September 3, 2025. This follows the successful resolution of the cease trade order issued by the British Columbia Securities Commission (“BCSC“) on May 7, 2025 and revoked by the BCSC on May 22, 2025.
The Company acknowledges and appreciates the patience of its shareholders during this process and reaffirms its commitment to adhering to high standards of compliance and corporate governance.
Industry and Corporate Update
Background
The...
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Financial Results and Operational Update for the Full Year Ended June 30, 2025
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025.
Mesoblast Chief Executive Dr. Silviu Itescu said, “This has been a banner year for the Company, with achievement of FDA approval for Ryoncil®, the first and only FDA approved mesenchymal stromal cell (MSC) product in the United States and a successful commercial launch of the product for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients aged 2 months and older (“children”).”
”We are working tirelessly to transform Mesoblast into a fast-paced commercial biotechnology...